Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:44 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2401–2424 of 8,462 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Metabolism Disorder, Glucose Clear all

Conditions: Cardiovascular Disease, Obesity, Cancer, Diabetes
Interventions: Game-based intervention, Smartphone; Behavioral · Device
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 69 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Type 1 Diabetes Mellitus
Interventions: Islets of Langerhans transplantation; Biological
Lead sponsor: CellTrans Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Type 1 Diabetes
Interventions: Siltuximab; Drug
Lead sponsor: Carla Greenbaum, MD; Other
Eligibility: 18 Years to 45 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Type 1 Diabetes
Interventions: Liraglutide, Placebo; Drug
Lead sponsor: University at Buffalo; Other
Eligibility: 15 Years to 30 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Williamsville, New York

Conditions: Type 2 Diabetes Mellitus
Interventions: Saxagliptin, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years and older
Enrollment: 18,206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 202
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 199 more

Conditions: Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
Interventions: Vicadrostat, Empagliflozin, Placebo matching Vicadrostat; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 11,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 208
States / cities: Anniston, Alabama • Fairhope, Alabama • Guntersville, Alabama + 171 more

Conditions: Lipodystrophy
Interventions: hu Leptin (A-100); Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetes Mellitus
Interventions: Role modeling in Shared medical appointments to Promote Establishing Collaborative Teams (ReSPECT); Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 25 Years to 85 Years
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Preventive Health Services, Health Communication
Interventions: Values affirmation, No affirmation; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older · Female only
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Oakland, California

Conditions: Diabetes
Interventions: Literacy/Numeracy oriented educational intervention, Control Group; Behavioral
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Hypertension, Diabetes Mellitus
Interventions: CVRS Intervention; Behavioral
Lead sponsor: Korey Kennelty; Other
Eligibility: 18 Years and older
Enrollment: 542 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 14
States / cities: Pocatello, Idaho • Chicago, Illinois • Mahomet, Illinois + 11 more

Conditions: Gestational Diabetes
Interventions: Sleep extension, Healthy living; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diabetes
Interventions: Not listed
Lead sponsor: DexCom, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Idaho Falls, Idaho

Conditions: Type 1 Diabetes Mellitus
Interventions: Usual Care, Transdisciplinary Care-In Person & Telehealth; Other · Behavioral
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 11 Years to 17 Years
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 3
States / cities: Wilmington, Delaware • Jacksonville, Florida • Orlando, Florida

Conditions: Diabetic Neuropathies
Interventions: CBD; Drug
Lead sponsor: Pure Green; Industry
Eligibility: 21 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Sterling Heights, Michigan

Conditions: Morbid Obesity, Metabolic Syndrome, Diabetes Mellitus, Hypertension, Obstructive Sleep Apnea of Adult
Interventions: GLP-1 receptor agonist; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Type 1 Diabetes Mellitus
Interventions: Rituximab-pvvr, Abatacept, Sterile Sodium Chloride; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 8 Years to 45 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 17
States / cities: Orange, California • Palo Alto, California • San Francisco, California + 14 more

Conditions: Liver Transplantation, Metabolic Syndrome X, Obesity
Interventions: Control group, Mediterranean diet, Protein-Sparing Modified Fast (PSMF); Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Atherosclerosis, Diabetes Mellitus
Interventions: troglitazone; Drug
Lead sponsor: Parke-Davis; Industry
Eligibility: 30 Years to 70 Years
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2000
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Type 1 Diabetes Mellitus
Interventions: Omnipod Horizon™ Automated Glucose Control System; Device
Lead sponsor: Insulet Corporation; Industry
Eligibility: 6 Years to 70 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 6
States / cities: Palo Alto, California • Denver, Colorado • Atlanta, Georgia + 3 more

Conditions: Metabolic Syndrome
Interventions: Xanthohumol; Dietary Supplement
Lead sponsor: Oregon State University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Type 1 Diabetes Mellitus
Interventions: Blood draw; Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2015
U.S. locations: 2
States / cities: Duarte, California • Loma Linda, California

Conditions: Diabetes Mellitus Type 2
Interventions: PF-05175157, Midazolam, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Type 2 Diabetes Mellitus
Interventions: HE3286, Placebo; Drug
Lead sponsor: Harbor Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 22
States / cities: Anaheim, California • Beverly Hills, California • Buena Park, California + 17 more

Search by objective public record fields.

STEP AND GO: A Study of Technology-based Exercise Promotion

Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol

Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes

Anti-diabetic Effects of Liraglutide in Adolescents and Young Subjects With Type 1 Diabetes

Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

Leptin to Treat Lipodystrophy

Interprofessional Training to Improve Diabetes Care: The ReSPECT Trial

Patients Engaged in Prevention: Enhancing Outreach to Increase Patient Engagement in Diabetes Prevention

Improving Care for Patients With Diabetes and Poor Numeracy Skills

Dissemination of the Cardiovascular Risk Service

Sleep Duration in Women With Previous Gestational Diabetes

Observational Study to Evaluate the Effectiveness and Safety Study of the Dexcom G4™ Continuous Glucose Monitoring System

Transdisciplinary Versus Usual Care for Type1 Diabetes in Adolescence

The Use of a Water Soluble Under the Tongue (Sublingual) CBD Tablet for Treating Pain Associated With Diabetic Peripheral Neuropathy

Impact GLP-1 Agonists Following Bariatric

Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes

Mediterranean Diet and Protein-Sparing Modified Diet for Metabolic Syndrome in Liver Transplant Recipients

TART - Troglitazone Atherosclerosis Regression Trial

Prepivotal Omnipod Horizon™ Automated Glucose Control System

Xanthohumol and Metabolic Syndrome

Detection of Human Beta Cell Death in Type 1 Diabetes Mellitus (T1DM) by Methylation Specific Polymerase Chain Reaction (PCR)

Multiple Dose Safety Tolerability, Pharmacokinetics And Midazolam Interaction In Healthy Overweight And Obese Subjects

Safety, Tolerance and Activity of HE3286 in Patients With Type 2 Diabetes Mellitus